Complete Story
 

05/21/2013

TARCEVA (erlotinib) Now Approved for NSCLC

TARCEVA (erlotinib) tablets is NOW APPROVED as first-line therapy for metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations  READ MORE